FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Bulk Compounding List

The FDA has proposed excluding weight loss drugs from Novo and Lilly from the bulk compounding list, a move that would benefit the pharmaceutical companies.

30 Apr, 15:02 — 30 Apr, 15:02

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual27d ago

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's ⁠drug shortage ⁠list.

Read full article →

PERSPECTA

PERSPECTA

FDA Proposes Excluding Novo, Lilly Weight Loss Drugs from Bulk Compounding List

Sources

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Manila Water Prepares for Severe El Niño

Philippines Lawmakers Call for Review of Energy Policies Amid High Costs

DA Plans Cloud Seeding in Negros Occidental to Mitigate Crop Damage

PERSPECTA